ideasIdea
An asynchronous expert second opinion for every new advanced-cancer diagnosis
Every patient newly diagnosed with advanced cancer would have their records reviewed by an expert centre within a week, without travelling. The review often changes the plan.
Second-opinion studies consistently show that expert review changes diagnosis or management in a substantial minority of cases, especially in pathology and molecular interpretation. Providing an asynchronous, record-based expert review for all new stage IV diagnoses, funded by payers and delivered by accredited centres, would spread expertise without moving patients. AI could pre-structure the record to reduce reviewer time.
Hypothesis
Universal second opinion will change management in at least 15% of advanced cancer cases and increase enrolment in appropriate trials and use of targeted therapy in eligible patients.
Rationale
The value of second opinion is established; the gap is access, which is inequitably distributed toward well-informed patients near academic centres.
What would test it
A payer pilot in one region offering review to all new stage IV patients, measuring change in management, trial enrolment, and patient satisfaction.
Maturity
speculative
Who has to act
payer
Cost to try
Medium ($1M to $50M)
Years to first evidence
3
Bottlenecks it attacks
- Fragmented care and guideline gaps · Patients fall between specialists, wait for referrals and often do not get the treatment guidelines say they should.
- Knowledge reaches practice too slowly · Knowledge diffusion is slow: it takes years for a proven result to change what most patients receive, and no one can keep up with the literature.
- Trials enrol too few, too slowly · Fewer than one in ten adults with cancer joins a trial. Trials close for lack of patients, not lack of ideas.